Huimin Geng

This study maps syndecan expression across tissues and challenges SDC1 as a specific endothelial biomarker, showing its epithelial enrichment and potential role in trauma-induced injury.

The paper investigates the CD48-CD244 axis in multiple myeloma, showing CD48 enhances NK-cell activation but contributes to NK exhaustion and poor prognosis.

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

This study identifies enhancer heterogeneity as a driver of transcriptional differences in KMT2A::AFF1 ALL patients, revealing patient-specific enhancer activity at oncogenes.

This study identifies BRG1 as a critical target in Ph-like B-ALL, showing its inhibition leads to cell cycle arrest and improved survival in preclinical models.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

This study identifies PAF1 and FACT as essential for enhancer activity in MLL-AF4-driven leukemia by maintaining histone acetylation and enhancer-promoter interactions.